Response of segmental vitiligo to 0.05% clobetasol propionate cream.
Khalid
M
M
Department of Dermatology, Nishtar Medical College, Multan, Pakistan.
Mujtaba
G
G
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001284:Atrophy / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D002990:Clobetasol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D009824:Ointments; D012867:Skin / Q000187:drug effects / Q000473:pathology; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced; D012880:Skin Pigmentation / Q000187:drug effects; D013684:Telangiectasis / Q000139:chemically induced; D016896:Treatment Outcome; D014820:Vitiligo / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D009824:Ointments; D002990:Clobetasol